Lizza E.L. Hendriks
Impact in
- Oncology top 0.5%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
Papers in
-
- Lung Cancer Treatments and Mutations 118
- Lung Cancer Diagnosis and Treatment 57
- Brain Metastases and Treatment 34
- Oncology 136
- Lung Cancer Research Studies 69
- Cancer Immunotherapy and Biomarkers 53
- Co-authors
- Anne‐Marie C. Dingemans (89 shared papers)Benjamin Besse (42 shared papers)David Planchard (15 shared papers)Solange Peters (8 shared papers)Jordi Remón (40 shared papers)Egbert Frederik Smit (19 shared papers)Keith M. Kerr (4 shared papers)Giulia Veronesi (3 shared papers)
- Journals
- Annals of Oncology (34 papers)Journal of Thoracic Oncology (33 papers)Lung Cancer (32 papers)European Journal of Cancer (17 papers)Frontiers in Oncology (14 papers)
- Partner nations
- NetherlandsFranceItaly
In The Last Decade
Lizza E.L. Hendriks
252 papers receiving 8.2k citations
Lizza E.L. Hendriks's Hit Papers
Peers
Comparison fields: 5 of 122
- Oncology 3.9k
- Pulmonary and Respiratory Medicine 3.3k
- Cancer Research 615
- Immunology 540
- Genetics 250
Countries citing papers authored by Lizza E.L. Hendriks
This map shows the geographic impact of Lizza E.L. Hendriks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lizza E.L. Hendriks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lizza E.L. Hendriks more than expected).
Fields of papers citing papers by Lizza E.L. Hendriks
This network shows the impact of papers produced by Lizza E.L. Hendriks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lizza E.L. Hendriks. The network helps show where Lizza E.L. Hendriks may publish in the future.
Co-authors
The 25 scholars most cited alongside Lizza E.L. Hendriks, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 275 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer Hit paper breakdown → | 2018 | 842 |
| 2 | Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Hit paper breakdown → | 2023 | 558 |
| 3 | Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial Hit paper breakdown → | 2020 | 516 |
| 4 | Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ Hit paper breakdown → | 2021 | 409 |
| 5 | Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Hit paper breakdown → | 2023 | 403 |
| 6 | Non-small-cell lung cancer Hit paper breakdown → | 2024 | 247 |
| 7 | 2019 | 216 | |
| 8 | 2019 | 198 | |
| 9 | 2008 | 192 | |
| 10 | 2020 | 140 | |
| 11 | Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges Hit paper breakdown → | 2023 | 138 |
| 12 | 2015 | 112 | |
| 13 | 2022 | 107 | |
| 14 | 2014 | 106 | |
| 15 | 2015 | 104 | |
| 16 | 2022 | 100 | |
| 17 | 2020 | 96 | |
| 18 | 2021 | 95 | |
| 19 | Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study Hit paper breakdown → | 2024 | 89 |
| 20 | 2019 | 88 |
About Lizza E.L. Hendriks
Lizza E.L. Hendriks is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Radiology, Nuclear Medicine and Imaging and Immunology, having authored 275 papers that have together received 8.3k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (118 papers), Lung Cancer Research Studies (69 papers), Lung Cancer Diagnosis and Treatment (57 papers), Cancer Immunotherapy and Biomarkers (53 papers), Brain Metastases and Treatment (34 papers), Radiomics and Machine Learning in Medical Imaging (18 papers), Cancer Genomics and Diagnostics (17 papers) and Immunotherapy and Immune Responses (10 papers). The work is most often cited by research in Oncology (3.9k citations), Pulmonary and Respiratory Medicine (3.3k citations), Cancer Research (615 citations), Immunology (540 citations) and Genetics (250 citations). Lizza E.L. Hendriks has collaborated with scholars based in Netherlands, France and Italy. Frequent co-authors include Anne‐Marie C. Dingemans, Benjamin Besse, David Planchard, Solange Peters, Jordi Remón, Egbert Frederik Smit, Keith M. Kerr, Giulia Veronesi, Martin Reck and Dirk De Ruysscher. Their work appears in journals such as Annals of Oncology, Journal of Thoracic Oncology, Lung Cancer, European Journal of Cancer and Frontiers in Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.